Remdesivir treatment and transient bradycardia in patients with coronavirus diseases 2019 (COVID-19)

•Remdesivir is the only antiviral approved for COVID-19.•Remdesivir treatment was associated with transient bradycardia.•Bradycardia did not cause any severe clinical manifestation.

Saved in:
Bibliographic Details
Published in:The Journal of infection 2021-08, Vol.83 (2), p.237-279
Main Authors: Pallotto, Carlo, Blanc, Pierluigi, Esperti, Sara, Suardi, Lorenzo Roberto, Gabbuti, Andrea, Vichi, Francesca, Mecocci, Lorenzo, Esposti, Anna Degli, Pierotti, Piera, Attala, Letizia, Salomoni, Elena, Baragli, Filippo, Francisci, Daniela, Pietro, Massimo Antonio Di
Format: Article
Language:English
Subjects:
Letters to the Editor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Remdesivir is the only antiviral approved for COVID-19.•Remdesivir treatment was associated with transient bradycardia.•Bradycardia did not cause any severe clinical manifestation.
ISSN:0163-4453
1532-2742
DOI:10.1016/j.jinf.2021.05.025